112 related articles for article (PubMed ID: 2095203)
21. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
22. The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution.
Foxwell BM; Blakey DC; Brown AN; Donovan TA; Thorpe PE
Biochim Biophys Acta; 1987 Jan; 923(1):59-65. PubMed ID: 3099852
[TBL] [Abstract][Full Text] [Related]
23. Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates.
Pincus SH; Wehrly K; Chesebro B
J Immunol; 1989 May; 142(9):3070-5. PubMed ID: 2540236
[TBL] [Abstract][Full Text] [Related]
24. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain.
Till MA; Zolla-Pazner S; Gorny MK; Patton JS; Uhr JW; Vitetta ES
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1987-91. PubMed ID: 2538826
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human CD4 elicits antibody responses different in epitope specificity from those that cellular CD4 elicits.
Reeves JP; Epstein SL
Mol Immunol; 1993 Jun; 30(8):765-73. PubMed ID: 7684821
[TBL] [Abstract][Full Text] [Related]
26. Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Candiani C; Franceschi A; Chignola R; Pasti M; Anselmi C; Benoni G; Tridente G; Colombatti M
Cancer Res; 1992 Feb; 52(3):623-30. PubMed ID: 1732050
[TBL] [Abstract][Full Text] [Related]
27. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of SIV infection with soluble receptor molecules.
Allan JS; Strauss J; Buck DW
Science; 1990 Mar; 247(4946):1084-8. PubMed ID: 2309120
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the tertiary structure of soluble CD4 bound to glycosylated full-length HIVgp120 by chemical modification of arginine residues and mass spectrometric analysis.
Hager-Braun C; Tomer KB
Biochemistry; 2002 Feb; 41(6):1759-66. PubMed ID: 11827520
[TBL] [Abstract][Full Text] [Related]
30. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.
Guo Q; Ho HT; Dicker I; Fan L; Zhou N; Friborg J; Wang T; McAuliffe BV; Wang HG; Rose RE; Fang H; Scarnati HT; Langley DR; Meanwell NA; Abraham R; Colonno RJ; Lin PF
J Virol; 2003 Oct; 77(19):10528-36. PubMed ID: 12970437
[TBL] [Abstract][Full Text] [Related]
31. Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Burbage C; Tagge EP; Harris B; Hall P; Fu T; Willingham MC; Frankel AE
Leuk Res; 1997 Jul; 21(7):681-90. PubMed ID: 9301690
[TBL] [Abstract][Full Text] [Related]
32. Internal-image anti-idiotype HIV-1gp120 antibody in human immunodeficiency virus 1 (HIV-1)-seropositive individuals with thrombocytopenia.
Karpatkin S; Nardi MA; Kouri YH
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1487-91. PubMed ID: 1741404
[TBL] [Abstract][Full Text] [Related]
33. HIV-infected cells are killed by rCD4-ricin A chain.
Dis Markers; 1990; 8(1):31. PubMed ID: 2311347
[No Abstract] [Full Text] [Related]
34. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.
Autiero M; Abrescia P; Dettin M; Di Bello C; Guardiola J
Virology; 1991 Dec; 185(2):820-8. PubMed ID: 1720590
[TBL] [Abstract][Full Text] [Related]
35. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
36. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.
Turner S; Tizard R; DeMarinis J; Pepinsky RB; Zullo J; Schooley R; Fisher R
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1335-9. PubMed ID: 1741386
[TBL] [Abstract][Full Text] [Related]
37. Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS.
Clerici M; Yarchoan R; Blatt S; Hendrix CW; Ammann AJ; Broder S; Shearer GM
J Infect Dis; 1993 Oct; 168(4):1012-6. PubMed ID: 8376811
[TBL] [Abstract][Full Text] [Related]
38. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
39. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion.
Pollard SR; Meier W; Chow P; Rosa JJ; Wiley DC
Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11320-4. PubMed ID: 1763044
[TBL] [Abstract][Full Text] [Related]
40. The role of binding ligand in toxic hybrid proteins: a comparison of EGF-ricin, EGF-ricin A-chain, and ricin.
Herschman HR
Biochem Biophys Res Commun; 1984 Oct; 124(2):551-7. PubMed ID: 6333873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
